Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

71.4%

5 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 3(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06456580Phase 3Recruiting

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Role: lead

NCT07404865Phase 3Recruiting

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Role: lead

NCT06456567Phase 3Withdrawn

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Role: lead

NCT05306574Phase 3Terminated

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Role: lead

NCT05984199Phase 1Terminated

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Role: lead

NCT04849910Phase 1Terminated

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Role: lead

NCT05309733Terminated

A Long-term Follow-up Study of Patients Who Received VOR33

Role: lead

All 7 trials loaded